Hypoxia-Inducible Factor Targeting

Hypoxia-inducible factor targeting addresses tumour adaptation to low-oxygen microenvironments promoting angiogenesis. HIF-1 alpha stabilisation increases pro-angiogenic factor production. VEG factor inhibition prevents neovascularisation. Combination targeting of HIF and VEGF pathways enhances efficacy. Resistance mechanisms including HIF-independent angiogenesis complicate therapy.

Biomarker assessment identifies HIF-driven tumours. Hypoxia imaging confirms low-oxygen regions. Regulatory submissions justify HIF targeting rationale. Clinical translation demonstrates therapeutic benefit. Emerging technologies improve HIF pathway targeting.